OrgantreeBlockchain-based Communication Portal for Organ Donation

W H I T E P A P E R

TABLE OF CONTENTS

1. Abstract 3

2. Executive Summary 4

3. Market Analysis & Core Challenges 53.1 Introduction3.2 Core market challenges3.3 How Organtree is different

4. Organtree Solution 74.1 Overview4.2 Organtree unique selling proposition

5. The Organtree Product 5.1 OGT Blockchain5.2 OGT Bioprint Lab5.3 OGT Medical Portal5.4 OGT Angel Messenger

6. Token Economy6.1 Dual purpose of the OGT utility token6.2 OGT token growth potential6.3 OGT token disclaimer6.4 Distribution of tokens

7. Road Map

8. Team

9. Disclaimer

10. Risk Assessment

11. References

10

13

16

18

21

22

26

1.AbstractBefore we begin, we would like to thank you for taking the time to read the official Organtree Whitepaper. Health professionals, public donors, blockchain specialists, academics, health researchers, and business advisors have jumped on a journey to develop a project that could save the lives of millions in need of an organ transplant.

We, at Organtree, would like to introduce you to the next generation of communication portal for organ donation . Following an extensive research performed in the past 4 years, we’ve come to the conclusion that the waiting list for receiving an organ is never-ending is most countries around the world. What we’re trying to do is to bring people together on a platform where they can communicate, and therefore build a global database readily available to medical entities and institutions that could better address the issue of organ donation.

Organtree is a technologically advanced platform created around a legal framework for medical professionals. It is meant to provide them with confidential live data so that they can search the globe for matching patients who are the most in need of an organ for life saving surgery.

The mission and vision of our platform is bold, visionary, but necessary . By leveraging the Block Lattice technology, based on the NANO blockchain, we will assign each user their own blockchain and their data will be immutably kept on the OGT network. Smart contracts will facilitate the exchange of data between donors and recipients; they will also allow hospitals to access patient data if an agreement is made. Our ultimate objective is to develop an R&D health centre for 3D organ printing. We’re looking to partner with the top bioprinting companies to help us take our vision beyond borders. Throughout the research phase of our project, we will build the Organtree Live App as well as several Organtree Medical Facilities APIs Organ Tree does not intend in any way to be an organ trading platform. We are building a decentralized platform where medical entities and donors can connect directly, and help save lives on a global level.

Organtree does not sell or trade in organs or condone any sort of illegal activities. Furthermore Organtree is not involved in the matching process and does not benefit financially if a match is made. The Organtree solution is not just good for the donor, recipient or hospital, but it will also benefit insurance companies who are financially exposed annually due to the costs involved in keeping their patients alive on life saving apparatus whilst waiting for a match.

3

2.Executive SummaryWith over 2,000 active members and over 2 years of experience in the medical field, Organtree is a trusted medical company with an already fully-functional app in place. On Organtree, people are invited to register as organ donors, recipients, or medical staff, and get access to a global database that might save lives. Find out more about Organtree, here: https://organ-tree.com/

In order to streamline access to more accurate information regarding organ donation, we’ve decided to take the Organtree mission and vision a few steps ahead, and build a Blockchain-based communications portal between donors, recipients and their families, as well as medical entities and health organizations. One of Organtree’s main objective for the future is to build an fully-functional R&D centre for organ printing. Following the successful completion of our ICO, we will settle on a friendly location and together with our partners we will take bioprinting technology to the next level.

Bioprinting has emerged as one of the most promising technologies for the fabrication of both artificial tissues and human organs. We, at Organtree, strongly believe that the new technology is the future of healthcare. By building a research centre, we will have the resources necessary to transform a futuristic concept into reality.

As far as our OGT utility token is concerned, it will serve a dual purpose. We plan to on-board funeral directors and make the OGT token a universal payment method for the funeral costs of the donors. In the future, upon the successful development of our R&D center, OGTs will be used to pay for artificial organs, and therefore the save the lives of hundreds of people currently on transplant waiting lists. The team behind Organtree is well-aware the process might take several years before being put into practice. But we are confident that by creating a decentralized communications portal between donors and hospitals, we have real chances of trans-forming our project into reality. Organtree will not get involved in any way in the matching process between a patient and a donor. We are merely a “digital meeting point” designed to take communication beyond borders. As soon as a connection is made via the Organtree medical API, a smart contract is created between the parties involved, and the OGT tokens will be placed into the OGT Escrow system.

4

3.Market Analysis & Core Challenges3.1 Introduction

Despite breakthroughs in both medicine and technology over the past 10 years, there is a clear gap between organ supply and demand. Further progress is needed to make sure all active candidates get a fair chance of receiving a transplant. In 2015, an NHS report1 warned about the organ donation crisis in the UK. With over 19 million people, only 31%2 are registered on an organ donor’s list. The concerning shortage in healthy organs for transplant purposes is also a global issue. The discrepancy between people waiting for a transplant and the organs available continues to increase at an alarming rate.

The number of people suffering from some sort of disease that may require a transplant, such as liver disease and type 2 diabetes has been increasing. In 2014, 422 million adults3 spread around the world suffered from diabetes. The number increased tremendously from 108 million in the 1980s. In the US, there are over 114,000 active candidates waiting for an organ transplant. 83% are waiting for a kidney transplant. 2 out of 3 people are above 50 years old, and n early 2,000 children are under the age 184.

3.2 Core market challenges

Major global market challenges concerning the organ transplant industry are linked to:

- Cross-border regulation for organs being harvested and transplanted beyond national borders- Lack of transparency due to bureaucracy and unethical practices- Lack of time physicians have for harvesting an organ. This usually means that organs don’t go to the patient that most needs it, but to the patient closest to the harvesting location.- Organ trafficking in underdeveloped countries

According to the National Kidney Foundation5, over 122,000 patients in the United States were on the waiting list for a transplant in 2014. Although advanced technologies have managed to increase the number of tissue banks, there is a shortage in donors, too. One of the main reasons causing the shortage is lack of awareness. Leaving bureaucracy and all of the above-mentioned concerns aside, many people are not aware that they can donate.

5

3.3 How Organtree is different

Organtree aims to become a global communications portals in the healthcare industry powered by Blockchain technology. Our project is not just different, but also unique because it tackles an untapped market: the lack of communication and collaboration in the organ transplant industry on a global level. Considering the decreasing number of viable, available organs together with a corrupt system where organs are assigned to the wealthiest and not to the sickest, the Organ Treen vision is to ease the process with its decentralized communications portal.

Time efficiency increased with organ bioprinting (R&D Research Center)

Despite technological advances in the healthcare industry, there’s still a lack of transparency when it comes to WHO is entitled to receive an organ transplant and WHEN. The process can take years and many people cannot afford to stay on organ waiting lists forever. With our vision to build an R&D center for bioprinting organs, we will bridge the gap between the time spent looking for a donor and the amount of time required to get a transplant, our platform won’t just speed real-time organ transplants, but it will also reduce the time spend on an organ transplant list.

From a general perspective, a transplant may come from 2 sources:

- Organ Donation Register6 (UK) or the Organ Procurement and Transplant Net work7 (OPTN in the US). These are the official sources where people can sign up and become a donor or a patient. While they might seem safe, the process is time consuming. The amount of paperwork involved, the hassle of waiting until the officials find a match is nerve wracking, not to mention life threatening.- Illegal organ procurement8 on the black market, which is unofficial, risky, and unethical. However, when a loved one’s life is at stake, there’s nothing a per son won’t do to save them.

With over 120,000 people waiting for an organ transplant9 in the US and 70% of families changing their minds about donation because of religious beliefs or superstition, a viable solution needs to be found. This is where Organ Tree comes in. Powered by a legal framework, our project aims to provide better clearance to both donors and patients, as well as offer transparent compensation to a donor’s relatives for their willingness to save a life.

Decentralized communication between hospitals (OGT Life App)

6

The current donor matching system is ruled by entities such as UNOS. When a patient is accepted on an organ transplant list, they are being registered in a centralized, national computer; the network links all transplant candidates and donors, therefore puts them on a never ending waiting list. We, at Organtree, aim to decentralize the way communication happens between donors, recipients, and hospitals. Although we do not get involved in the process - because each hospital has particular licences, rules and regulations to do so - we are providing institutions with better alternatives to connect.

We’ve already started reaching out to hospitals and medical institutions around the world to join our project in order to access a diverse database of donors. Organtree’s mission is to raise awareness and solve the lack of knowledge people have when it comes to organ donation.

4.Organtree Solution4.1 Overview

From a general perspective, a transplant may come from 2 sources:

- Organ Donation Register10 (UK) or the Organ Procurement and Transplant Network11 (OPTN in the US). These are the official sources where people can sign up and become a donor or a patient. While they might seem safe, the process is time consuming. The amount of paperwork involved, the hassle of waiting until the officials find a match is nerve wracking, not to mention life threatening.- Illegal organ procurement12 on the black market, which is unofficial, risky, and unethical. However, when a loved one’s life is at stake, there’s nothing a person won’t do to save them.

With over 120,000 people waiting for an organ transplant13 in the US and 70% of families changing their minds about donation because of religious beliefs or superstition, a viable solution needs to be found. This is where Organtree comes in. Powered by a legal framework, the project aims to provide better clearance to both donors and patients, as well as offer transparent compensation to a donor’s relatives for their willingness to save a life.

7

4.2 Organtree unique selling proposition

Every ten minutes, someone is added to the national transplant waiting list. On average, 20 people die each day while waiting for a transplant. A single organ donor can save up to 8 human lives. Organtree is a decentralized, one-of-a-kind network that aims to become a global connector in the organ donation industry. By launching an ICO, we’re jumping a journey to solve a global issue and put an end to the existing organ scarcity in the healthcare system.

Apart from building a decentralized communications hub between donors, recipients and their families, we’re launching an ICO to raise funds and build an R&D center for organ printing in the future. At this point, we’ve actively negotiating with CXO, a leading tissue and organ printing company to help us perform an in-depth research on what is truly needed for our research center, including: hiring leading staff, purchasing equipment, dealing with maintenance costs, logistics, and operations.

Even though today’s technological developments aren’t sophisticated enough to be able to print complex human organs, researchers are capable of bioprinting less complex organs. To better understand our mission & vision, we’re presenting you several use cases on the benefits of bioprinting organs:

Use case #1 (3D bladder)

Researchers at Wake Forest University in the state of North Carolina, US, managed to extract cells from the poorly functioning bladder of one of their patients. After cultivating the cells with added nutrients, a 3D mould was bioprinted for the patient’s bladder. The 3D mould was transplanted into the patient’s body after being carefully supervised in an incubator.

The team behind the Organtree project is working on fulfilling several important goals for its Organtree platform:

Develop a decentralized communication portal for organ donation

Build the Organtree Life App

Organtree Medical Facilities API

Develop an R&D center for 3D bioprinting of organs

8

Use case #2 (3D heart-on-a-chip)

In 2016, several researchers at Wyss Institute , Harvard University managed to 3D print a heart-on-a-chip with integrated sensors, the first in the world. Currently under further research, the device is a micro-physiological system that can mimic human tissue behavior.

Use case #3 (human tissue as a cardiac patch)

BioLife4D is a 3D printing startup that recently managed to produce human tissue in the form of a cardiac patch, thus proving once more that organ printing technol-ogy is closer than ever to producing viable organs for transplant. The cardiac patch was developed in Houston, at a research facility, and it is derived from the white blood cells of a patient.

Chief science officer for BioLife4D, Ravi Birla, mentioned that “the ability to bioprint human cardiac tissue provides a clear and rapid pathway towards bioprinting hu-man hearts”. The company plans to continue the research by moving on to bioprinting valves, blood vessels and a mini-heart. In the future, they’re hoping to use a patient’s own white blood cells to create a viable heart ready to be transplanted onto a living patient. Founder of BioLife4D says that “we’re talking about doing will solve the problem of supply and enable people on waiting lists to get hearts. “Unlike a lot of other things that happen with medical advancements, this will be a win-win for everybody.”

Organtree strongly believes that bioprinting fully functional internal organs is no longer an impossible mission. Technological advancements are happening at a very fast pace, and upon the successful completion of our ICO, we’ll have the means necessary to speed up the research and give everyone a chance at a better life sooner than anticipated.

9

5.The Organtree ProductThe Organ Tree platform is the first of its kind. It has been designed to provide authorized, vetted medical institutions with the capability to search the globe confidentially, and find a match to their patients who are the most in need of an organ transplant. Main features include:

- Access to a global network of donors, recipients, medical institutions, life insurance companies via the OGT Medical Portal- Smart contract system to facilitate the exchange of data between donors and recipients via the OGT Blockchain- Secure, trusted, and private access to a global database of donors via the OGT Angel Messenger App- Future access to 3D bioprinted organs via the OGT Bioprint Lab

5.1 OGT Blockchain

OGT uses Block Lattice technology based on the NANO blockchain. OGT will assign each user their own blockchain and their data will be immutably kept on the OGT network. Smart contracts will facilitate the exchange of data between donors and recipients; they will also allow hospitals to access patient data if an agreement is made.

10

5.2 OGT Bioprint Lab

To be able to put our vision in context and start the development of our R&D laboratory on organ bioprinting, we will partner with some of the best 3D printing companies in the world. We aim to build a fully-functional facility that will focus exclusively on researching cutting-edge bioprinting methodologies and techniques to understand the physics of bioprinting processes.

At this point, we’re negotiating with renowned 3D companies to join the Organtree mission. We’ll keep you updated with our progress, and as soon as we close a deal, we will post the news on our ICO website and official Organtree Medium portal.

5.3 OGT Medical Portal

The OGT Medical Portal will invite medical entities and other healthcare facilities to sign up and register their contact details before getting access to the OGT database. Following this step, the portal will allow them to: - Access and search through our database for potential donors or recipients- Access contact details in order to potentially find organ requests or organ matches within the decentralized OGT database- Send direct messages to potential patients- Publish articles/newsletters and share them with the OGT community base

The overall Organtree communication hub is unique in every sense because we’re building a community with the ultimate goal to raise awareness and streamline access to communication between donors and recipients. After the registration process has been completed, all OGT platform members will be able to connect one-on-one.

11

5.4 OGT Angel Messenger

The OGT Angel Messenger app will be Organtree’s first product release, following the successful completion of our ICO. We already have the centralized version of the app available at: https://organ-tree.com/

App functions for donors & recipients:

Donors and donor recipients interested to join the Organtree communication portal will have to download the app, and complete basic personal information to complete the registration process:

- Full name- Location ( city, country, state)- Medical facility or hospital being cared at- Blood type- Medical condition- Health history

After the donor or recipient agrees to the Organtree terms and conditions, they will enter the Organtree database where their profiles will be revealed to medical institutions and hospitals part of the Organtree network as well. The hospital/medical facility will scout the database for matching donors, following which a smart contract is created, and all communication between the medical entity and the donor/donor’s relative will be private and secure. Organtree does not interfere in the process, and the hospital will handle the legal paperwork involved in case the donor proves to be a match.

When, and IF a match is found, and after all legal formalities have been completed, Organtree will interfere by putting the hospital/health organization in contact with a funeral director to handle funeral costs of the deceased. The organ recipient will be informed by their hospital/health insurance company/medical facility that they will be able to communicate with the donor’s relative via the Organtree secure chat to complete funeral costs, which will be made in OGT tokens.

App functions for medical institutions, hospitals, and healthcare companies One of the main benefits of Organtree’s Angel Messenger App is the cross-border access to a vast, global database of organ donors. In order to access the database and enter the OGT communication portal, medical entities will have to download the app, and enter basic information to complete the registration process.

12

- Name of the facility, including registration documents and paperwork that prove the facility exists and that it operates in the best interest of their patients.- Location (city, state, country)- Brief description of the facility/organization

Following the successful completion of the registration process as a hospital/health facility, the organization will be provided access to the Organtree database of donors. The app will serve as a secure, trusted, fully decentralized communication medium between donors/donors’ relatives and medical entities via the Organtree messenger chat system. The medical facility will be able to contact a potential donor or relative of a donor and engage on a one-on-one chat to discuss donation terms IF a potential match has been found. All transactions between the two parties involved will be made in OGT tokens.

6.Token Economy6.1 Dual purpose of the OGT utility token

The Organtree communications portal will be based on the NANO blockchain. It will have its very own utility token called the OGT token, which will serve two main purposes:

A direct payment method to funeral directors. After all legal paperwork has been filed, and a hospital has performed a successful operation between a donor and recipient, an immutable smart contract will be created on Organtree. The parties involved in the process will be able to chat one-on-one and agree on a certain amount of OGT tokens to cover funeral costs. Following this step, Organtree contacts one of our onboarded funeral directors who accepts to cover the funeral costs in OGT tokens.

-

13

- A second use for our OGT token is a visionary approach we hope to achieve following the successful development of our bioprinting lab. We plan to build a fully-functional, authorized research center, where patients can purchase bioprinted organs with OGT tokens.

DISCLAIMER : Organtree will not interfere in any way in the organ procurement process. All legal matters will have to be solved in advance between the hospital/medical facility, organ donor and recipient. We are merely a decentralized communication hub that provide borderless access to a database where everyone canconnect,engage in private conversations, and discuss the possibility of organ donation. Organtree serves as a payment gateway to cut back on high costs pertaining to cross-border transactions, therefore we are not bound by any sort of licensing or agencies.

6.2 OGT token growth potential

At this stage in our project, we can only make projections and assumptions regarding the growth potential of our OGT token. We predict that the value of our token will increase in the foreseeable future because:

- We’re building a global database where people can get access to organ do nors only if they sign up on the Organtree platform. On centralized platforms, it is not possible to do so because every country has its own rules and regulations as far as access to organ donors is concerned. There is no universal platform to include all organ donors in one place, and that’s exactly what we’re trying to develop.

- We predict that the price will skyrocket when we launch our R&D center. The potential of bioprinting technology is huge, and since there’s no organization that provides bioprinted organs yet, we aim to become the first in the world to do so.

6.3 OGT token disclaimer

The OGT token sale represents a voluntary contribution towards the execution of the product’s vision by its current and future team. The OGT token does not grant any direct equity stake nor profit sharing. It does not represent an ownership right or claims in the Organ Tree ecosystem, revenues or intellectual property, either present or future.

14

Despite Organ Tree team’s best efforts and diligence to bring this project forward, all contributors should be aware that their contributions are not refundable and accept the inherent risk of project failure at any stage of development. This implicit risk is associated with any and all uncertainty of backing cutting-edge technologically-focused entrepreneurial projects, and can be affected by either internal or external factors that are out of the control scope of the team.

Additionally, contributions may be subject to any applicable compliance regulations. The OGT token can be used on the Organ Tree platform, with a corresponding utility value inside the ecosystem. The OGT token does not qualify as a security and does not provide a contributor equity share in the legal structure of any of the Organ Tree entities.

6.4 Distribution of tokens

Blockchain: NANO Blockchain, lattice technologyToken Sale: Q4 of 2018Pre-ICO Stage 1 Aug 2-Sept 1 +40% tokens Stage 2 Sept 1 - Oct 1 +25% tokens Stage 3 Oct 1 - Nov 1 +15% tokens

I CO start time: November 1st, 2018 12:59 AMICO finish time: February 1st, 2019 12:58 AM

Acceptable currencies: ETH, BTC, LTC, EUR, USD, GBPNumber of tokens for sale: 1 250 000 000 OGT

Tokens exchange rate: 1 ETH = 32000 OGTMinimum transaction amount: 0.5 ETH

15

Organ Tree becomes a registered medical company

The official launch of the Organ Tree website

Online marketing campaign begins with the purpose to increase awareness

Organ Tree launched a campaign on lndiegogo

Organ Tree exceeded 20K on social media

Preparations for developing the Organ Tree ICO begin

Pre ICO launchOnboard medical & healthcare providersOnboard health organizations

The Release of the Organ Tree prototype app (beta)

Organtree begins to look into bioprinting technology, and decides to investigate the possibility of developing an R&D center for bioprinting organs

The Organ Tree app becomes fully functional and available to everyone globally

500+ people signed up with Organ Tree in first 2 months after launch

Organ Tree whitepaper version 1.0

Organ Tree ICO website launch

Organ Tree is endorsed by top medical institutions and closes deals with medical entities worldwide

7.Road Map

2016 Q1

2016 Q2

2017 Q4

2018 Q2

2018 Q3

16

The Organ Tree network goes global with over 6000+ transplant recipients Organtree becomes the world’s leading blockchain-based organ donation facilitator with over 500,000 subscribers

Over 2000 medical facilities worldwide are now part of the Organ Tree Platform

Organ Tree becomes a viable decentralized communications platform for 2000+ members, including donors, recipients, hospitals & other medical entities

Further focus on global marketing & advertising the OGT products (OGT Life App, Medical facilities APIs)

Other successful partnerships with medical companies are officially announced Organtree continues to expand to

global target markets, strengthening its team and advisory board

Organtree closes partnerships with at least 3 of the world’s most important 3D printing companies to begin the development of its R&D facility on bioprinting

The Organtree foundation becomes fully accredited to run an R&D facility on bioprinting organs, and begins testing the technology.

The 3D BIOprinting facilities will located in each major continent around the globe to ensure fast access to bioprinted organs to all members.

Organ transplants are now quicker than ever. We will be proud to release “Organtree bubbles” consisting of a team of surgeons around the globe who are able to perform the needed operation at the closest hospital.

Pre- ICO & ICO launch

Increase visibility of the Blockchain-based Organtree communications portal globally

Further research & development to improve the OGT Life App

Organtree officially decides to partner with global 3D printing companies to start the research phase of its bioprinting research facility

Organtree lists its OGT token on major global exchanges

Launch of the Organtree Blockchain app version 1.0 in a closed environment (OGT Angel Messenger App)

Organtree partners with global medical entities to educate & promote the Organtree mission, which is to create a decentralized communication hub between donors, recipients and other health organization around the world

2018 Q4

2019 Q1

2019 Q2

2019 Q3

2020

2023

2025

17

8.TeamRon Gologorsky

Founder & Director of Organ Tree

After joining the army at age 18, where he served as a paramedic for the elite fighter units of the IDF, Ron decides to specialize in the luxury hospitality management industry. In the early 2000s, he relocates to London to set up up Heart Watch Direct, UK’s 1st private emergency service for patients with heart disease. A few years later he founded Organ Tree, in the hopes of solving the human organ donation issue spread around the world.

Daniel Gologorsky

Operations Manager

Daniel Gologorsky specialises in logistics and operations for deliveries & product management for backend admin systems and live operations/customer service. With a background at Deliveroo, Daniel is currently on the board of Zebra Fuel Ltd, as Advisor of Operations. Daniel is working with Ron, his father, to further promote the Organ Tree project and save lives.

Saloni Bhojwani

Financial Advisor

With an MBA in Business Administration and a BA in Economics, Saloni is the Head of Growth for Zebra Fuel Ltd. Given her extensive experience in the financial industry, Saloni joins the Organ Tree team as a financial advisor.

Nick Green

Head of Growth

Nick Green joins the Organ Tree team as the Head of Growth. With extensive experience in business management and startup dynamics, Nick is also the Head of Strategy for UK’s first digital petrol station, Zebra Fuel Ltd.

18

Guy Fattal

Financial Project Manager

Guy Fatal Specializes in finance computing and project management. He has been with Organ Tree for over one year. Currently, he handles the company’s digital ad campaigns on Google, Facebook, Twitter, and Instagram.

David Hersh

Consultant

With over 25 years of experience in marketing and advertising, David joins the Organ Tree project as a skilled advisor of all things related to advertising strategy, concepts, and budgets. After studying Jewish law and applied best practices in the UK and Israel, David is in charge of providing useful advice and information with regard to the rulings of the Jewish courts and practices within the Jewish community on all aspects pertaining to organ donation.

Mordehay Vaturi MD.

Cardiologist

After graduating Magna cum Laude at Sackler Faculty of Medicine, Dr. Mordehay Vaturi pursued Cardiology as a profession. At the moment, he works in the Echocardiographuy Unit and Valvular Clinic section at the Rabin Medical Center in Israel. He specializes in valvular disease, heart failure, and stress echocardiography.

David Welch

Barrister

David Welch is an accredited solicitor who has advised and represented leading NHS employers in different legal matters. Over the years, David has also represented claimants and respondents appearing at the Employment Tribunal, Employment Appeal Tribunal, Court of Appeal, Supreme Court, High Court, and County Court. He also handles trusts and professional employees at Inquests, carrying out regulatory prosecutions for the Bar Standards Board, planning appeals, and contractual disputes.

19

Dr. Irit Iskevitch

Consultant

Dr. Irit Iskevitch joined the Organ Tree project as a consultant. With vast experience in the general dentistry field, she brings medical experience from a different domain, but she greatly believes in the mission pursued by our project.

Charles Warburg

UI/UX Graphic Designer

Charles is a skilled graphic designer that specializes in branding & identity and UI/UX design. He studied Graphic Design at Brighton University, and since then he has been working as a freelance designer for various companies and projects. Core proficiencies: Adobe Illustrator, Photoshop, and InDesign.

20

9.DisclaimerPLEASE REVIEW CAREFULLY THE PRESENT SECTION “LEGAL DISCLAIMER”. IF YOU HAVE ANY DOUBTS AS TO WHAT ACTIONS YOU SHOULD TAKE, WE RECOMMEND THAT YOU CONSULT WITH YOUR LEGAL, FINANCIAL, TAX OR OTHER PROFESSIONAL ADVISOR(S). No part of this White Paper is to be reproduced, distributed or disseminated without including this section “Legal Disclaimer”.

This white paper (“White Paper”) is meant to describe the currently anticipated plans of Organ Tree Ltd. (the “Company”) for developing a new blockchain-based digital asset called “Organtree” issued by the Company. This White Paper has not been subject to peer review.

Nothing in this document should be treated or read as a guarantee or promise of how or whether the Company or Organtree will develop or of the features, utility or value of the Company or Organtree. This White Paper outlines the Company’s current plans, which could change at its discretion, and the success of which will depend on many factors outside the Company’s control, including technological and engineering developments, market-based factors and factors within the money transfer and cryptocurrency industries, among others. Any statements about future events are based solely on the Company’s analyses of the issues described in this document. Those analyses may prove to be incorrect.

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER FOR SALE OF THE COMPANY’S ORGANTREE TOKENS, OR ANY OTHER MECHANISM FOR PURCHASING OGT TOKENS (SUCH AS, WITHOUT LIMITATION, A “SIMPLE AGREEMENT FOR FUTURE TOKENS”), AND SHOULD NOT BE CONSIDERED AS AN OFFERING OF SECURITIES IN ANY JURISDICTION. THIS WHITE PAPER DOES NOT INCLUDE OR CONTAIN ANY INFORMATION OR INDICATION THAT MIGHT BE CONSIDERED AS A RECOMMENDATION OR THAT MIGHT BE USED AS A BASIS FOR ANY INVESTMENT DECISION. ANY OFFER OR SALE OF OGT TOKENS OR ANY RELATED INSTRUMENT WILL OCCUR BASED ONLY ON DEFINITIVE OFFERING DOCUMENTS FOR THE APPLICABLE TOKENS OR THE APPLICABLE INSTRUMENT.

21

THE PURCHASE OF TOKENS ARE PARTICULARLY RISKY AND MAY RESULT IN TOTAL LOSS OF CAPITAL. THE ROADMAP PROPOSED FOR A NETWORK (I.E., A WHITE PAPER) IS SUBJECT TO CHANGE OR IMPLEMENTATION FAILURE. AN IMPLEMENTED NETWORK MAY NOT BE ADOPTED, RESULTING IN ITS TOKENS HAVING LOW OR NO VALUE. ONLY SOPHISTICATED INVESTORS WHO UNDERSTAND THE RISKS OF SPECULATIVE INVESTING IN NEW ASSET CLASSES AND HAVE CONSULTED THEIR OWN LEGAL AND FINANCIAL ADVISERS SHOULD PARTICIPATE IN ANY TOKEN OFFERING.

THIS WHITE PAPER INCLUDES FORWARD-LOOKING STATEMENTS. ALL STATEMENTS OTHER THAN STATEMENTS OF HISTORICAL INFORMATION PROVIDED HEREIN ARE FORWARD-LOOKING AND MAY CONTAIN INFORMATION ABOUT FINANCIAL RESULTS, ECONOMIC CONDITIONS, TRENDS AND KNOWN UNCERTAINTIES. SOME OF THESE FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TER-MINOLOGY SUCH AS “BELIEVES,” “EXPECTS,” “MAY,” “WILL,” “SHOULD,” “SEEKS,” “APPROXIMATELY,” “INTENDS,” “PLANS,” “ESTIMATES,” OR “ANTICIPATES” OR THE NEGATIVE THEREOF OR OTHER VARIATIONS THEREOF OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, INTENTIONS OR UNREALIZED INVESTMENT RESULTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO NUMEROUS RISKS AND ARE NECESSARILY DEPENDENT ON ASSUMPTIONS, DATA OR METHODS THAT MAY BE INCORRECT OR IMPRECISE AND MAY NOT BE REALIZED.

10.Risk AssessmentThe purchase of Organtree (OGT) tokens (hereinafter referred to as the “Token” or “Tokens”) may be associated with a high degree of risk. To protect the interests of Token’s potential purchasers, the Organtree team conducted an analysis of such potential risks and outlined the result of this analysis in this chapter of the White Paper.

IMPORTANT: THE LIST OF RISK FACTORS DESCRIBED BELOW IS NOT EXHAUSTIVE. IN ADDITION TO THE RISKS DISCLOSED IN THIS WHITE PAPER, THERE MAY BE EXISTING OTHER RISKS WHICH THE ORGANTREE TEAM AT PRESENT CANNOT REASONABLY FORECAST.

22

These risks can materialize in other forms of risk than those specified here. Prior to acquiring Tokens, each potential Token purchaser is advised to carefully review all the information and assess the risks of such purchase, including but not limited to, the risks set forth in this White Paper and to decide upon purchase of Tokens based on such assessment.

Technical and technological risks:

Risks of the blockchain. Tokens are released on Ethereum blockchain. In this regard, any malfunction of the Ethereum protocol may lead to a restriction in the use of Tokens, and / or to the fact that Tokens or the platform will func tion in an unforeseen manner.

Risk of hacker attacks on the platform, smart contracts, or Tokens. Tokens can be expropriated and/or stolen, by hacking Tokens, or otherwise. Hackers or other groups or organizations may attempt to intervene in a smart contract or Tokens in various ways, including, but not limited to, virus attacks, DDOS attacks, concerted attacks, network attacks, and denial of service attacks, and others. In addition, since the Ethereum platform is based on open source software, there is a risk that Ethereum smart contracts may contain intentional or unintentional errors or shortcomings that could adversely affect Tokens or lead to loss of Tokens, or loss of access or control Tokens. In the event of such an error or weakness of the software, there can be no remedy, and tokens owners are not guaranteed any compensation.

Risk of a hacker attack on the computer of the token holder, or loss of passwords / of private keys. Purchased Tokens can be stored by the token holder in her\his\its digital wallet or safe, for which a password, a digital key or a combination of digital keys is required. Accordingly, the loss of the necessary keys associated with such digital wallet or safe, can lead to loss of access to Tokens. In addition, any third party that gets access to such passwords and / or private keys (by way of getting (through hacking, or negligence of token holder) access to login credentials of token holders’ hosting-wallet, or otherwise), will be able to use Tokens of the token holder. Organtree assumes no liability for such losses.

Risk of using new technologies, and changes in technology in the future. Tokens and blockchain are fairly new and relatively untested technologies. Although at the moment they have largely proven their efficiency, reliability and security, there is no guarantee that in the future these technologies will not fail. Furthermore, as technological progress develops, flaws can be found in these technologies, and flaws will prevent their functioning in the way that they function at the moment.

23

Finally, there is no guarantee that these technologies will be compatible with any new technologies invented in the future. In the event of such incompatibility, use of Tokens and blockchain can be found unreasonable and stopped.

Risk of incompatibility of the crypto wallet service. An electronic crypto-wallet or wallet service provider that token holder has chosen \ will choose for obtaining and storing Tokens, must be technically compatible with the Tokens. Failure to comply with this condition may lead to the fact that the token holder will not be able to get access to her\his\ Tokens. Token holders must independently determine the fact of the compatibility of the crypto wallet she\he\ registered, with the Tokens. Organtree assumes no responsibility for any errors related to a wrong determination of the above fact.

Regulatory risks:

Risk of regulatory uncertainty. Regulatory status of cryptographic tokens, digital assets and blockchain technology, is unclear or not defined in many jurisdictions. It cannot be excluded that such technologies, and, in particular, Tokens, will in the future become subject to one or more (adopted or new) interpretations of laws (or other regulations), court judgments, or actions by various regulatory bodies around the world, including, but not limited to, the imposition of restrictions on the use or possession of digital tokens, such as Tokens. Such changes can adversely affect Tokens in various ways, including, for example, by determining that Tokens are regulated as financial instruments that require registration or compliance with other legal requirements and procedures. Organtree may stop distributing Tokens, developing a platform or terminating operations in a particular jurisdiction if the actions of regulatory authorities of the relevant jurisdiction make it illegal or not commercially viable to proceed.

Risk of inability to obtain, maintain or renew licenses and permits. As of the date of Tokens sale, there are no statutory requirements requiring Organtree to obtain any licenses and permits necessary for the sale of the Tokens, but the risk that such legislative requirements may be enacted in the future cannot be ruled out. In this event, the possibility of sale and further use of Tokens will depend on the procedure of issuing such licenses and permits, and on compliance with their terms. We cannot exclude that requirements of the law will be technically or economically achievable for Organtree. Organtree may stop distribution of Tokens, develop a platform or terminate operations in a particular jurisdiction in the event of economic, technological or other inability to obtain the required licenses or permits under such jurisdiction.

24

Risk of governmental action. The industry of blocking and reversing tokens is new, and simply by virtue of novelty can be subject to increased supervision and regulatory control, including investigations or enforcement actions. There can be no guarantee that the government will not study the activities of the parties involved. All this can be investigated, which in turn can have a significantly negative impact on Tokens and / or platform development.

Business risks:

Risk of failure in development. It cannot be excluded that for various reasons, including but not limited to, for reasons of insolvency of business or technological strategies or business arrangements, technological problems, emergence of new technologies, etc., that the model that Organtree developed and described in this White Paper, will not achieve the desired functionality, be inoperative, or work in a way different from what developers designed it for. Also, we cannot exclude the risk that for these or different reasons, development and implementation of the model can take longer than Organtree predicts at the moment, and when the model is ready, it will appear to be outdated and\or irrelevant.

Risk of insufficient implementation. It cannot be excluded that, for various reasons, including, but not limited to, for reasons of insolvency of marketing strategies, external constraints, or competitors’ actions, the model developed by Organtree and described in this White Paper may appear to be unpopular and\or unclaimed, lacking use and application.

Risk of dependence on third parties. Even after the launch, the model developed by Organtree and described in this White Paper will rely, wholly or partially, on third parties, for adoption and implementation of certain functions, as well as for continuing its development, maintenance and support. Though above-mentioned third parties are carefully selected by Organtree team, there is no insurance or guarantee that these third parties will do their job properly, or otherwise meet users’ needs, and this can have a significant adverse impact on the platform.

Risk of loss of cash. The project described in this White Paper, the model developed by Organtree, the platform being created, as well as any funds collected within the framework of the Token Sale described, are not insured. In case of failure of the project for any reason, loss of functionality of the Token or platform, there is no private or public insurance representative to whom token holders can apply for reimbursement.

25

11.References(1) https://www.organdonation.nhs.uk/news-and-campaigns/news/nhs-blood- and-transplant-reveals-nearly-49-000-people-in-the-uk-have-ha d-to-wait-for-a-transplant-in-the-last-decade/(2) https://www.telegraph.co.uk/news/health/news/11749503/Organ-donation-cri-sis-threatens-hundreds-of-lives.html (3) http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=F7D6C649C2C574AC9933B07C2AE0ED1E?sequ ence=1(4) https://organdonor.gov/statistics-stories/statistics.html(5) https://www.grandviewresearch.com/industry-analysis/transplantation-market(6) https://www.organdonation.nhs.uk/(7) https://docs.google.com/document/d/1x3q70pXI4lFzn7FKday7mZM49x6U_E62loa4L-yZR5E/edit# 8 https://www.decodedscience.org/organ-harvesting-hu-man-trafficking-black-market/56966(9) https://www.decodedscience.org/organ-harvesting-human-traffick-ing-black-market/56966(10) https://www.organdonation.nhs.uk/(11) https://docs.google.com/document/d/1x3q70pXI4lFzn7FKday7mZM49x6U_E62loa4L-yZR5E/edit# 12 https://www.decodedscience.org/organ-harvesting-hu-man-trafficking-black-market/56966(12) https://www.decodedscience.org/organ-harvesting-human-traffick-ing-black-market/56966

26

OrgantreeJoin Organtree.com now and

help create a better future